Association of angiotensin II type 1 receptor gene A1166C polymorphism with the presence of diabetes mellitus and metabolic syndrome in patients with documented coronary artery disease

Abstract Background: There are reported associations between a polymorphism of the angiotensin II type 1 receptor (AT1R/A1166C) gene and coronary artery disease (CAD), hypertension, and myocardial infarction in some populations. Objective: Investigate the association between A1166C polymorphism and CAD in an Iranian population. Methods: Four hundred and thirteen patients with suspected CAD were recruited. Based on coronary angiography, the patients were classified into CAD+ (n=315) and CAD- (n=98) groups defined as >50% and <50% stenosis of any major coronary artery, respectively. One hundred and thirty-five healthy subjects were also recruited as the control group. The AT1R polymorphism was assessed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) based method. Results: A higher frequency of the AC and CC genotypes and lower frequency of the AA genotype was observed in both CAD+ and CAD- groups, compared with the control group (p <0.05). CAD+ and CAD- groups also had a higher frequency of the C allele than controls (p <0.01). There was no significant difference in genotype and allele frequencies between hypertensive and non-hypertensive patients (p > 0.05). In addition, the AT1R genotype frequencies did not differ significantly among different subgroups of CAD+ patients, based on the number of affected coronary vessels (p >0.05). Conclusion: The frequency AT1R/A1166C polymorphism was higher among patients with some degrees of coronary stenosis who are candidates of coronary angiography.

Download Full-text

11β-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease

Genetics and Molecular Research ◽

10.4238/2012.august.31.10 ◽

2012 ◽

Vol 11 (3) ◽

pp. 3122-3132 ◽

Cited By ~ 10

Author(s):

F. Atalar ◽

B. Vural ◽

C. Ciftci ◽

A. Demirkan ◽

G. Akan ◽

...

Keyword(s):

Gene Expression ◽

Coronary Artery Disease ◽

Metabolic Syndrome ◽

Coronary Artery ◽

Hydroxysteroid Dehydrogenase ◽

Ascending Aorta ◽

Artery Disease

Download Full-text

Dyslipidemia: Reduction in Estimated Risk for Coronary Artery Disease After Use of Ezetimibe with a Statin

Annals of Pharmacotherapy ◽

10.1345/aph.1k140 ◽

2007 ◽

Vol 41 (9) ◽

pp. 1345-1351 ◽

Cited By ~ 5

Author(s):

John S Sampalis ◽

Stéphane Bissonnette ◽

Rafik Habib ◽

Stella Boukas

Keyword(s):

Diabetes Mellitus ◽

Coronary Artery Disease ◽

Metabolic Syndrome ◽

Coronary Artery ◽

Density Lipoprotein ◽

Lipid Lowering ◽

Open Label ◽

Statin Monotherapy ◽

Artery Disease ◽

The Impact

Background: The aim of lipid-lowering treatment is to reduce the risk for cardiovascular events. Patients not at target lipid levels while on hydroxymethylglutaryl coenzyme A reductase inhibitors (statin) monotherapy are at increased cardiovascular risk. Objective: To describe the impact of coadministration of ezetimibe with a statin on the estimated 10 year risk for coronary artery disease (E-RCAD) in patients with hypercholesterolemia and above-target low-density lipoprotein cholesterol (LDL-C) levels after statin monotherapy. Methods: Post hoc analysis was conducted of a prospective, open-label, single-cohort, multicenter Canadian study of 953 patients who were treated for 6 weeks with ezetimibe 10 mg/day coadministered with their current statin at an unaltered dose. For each patient, E-RCAD at baseline and at 6 weeks was calculated using the Framingham model. The primary outcome measure of the analysis was the change in E-RCAD. Results: A total of 825 patients with data at baseline and 6 weeks were included in the analysis. There were 423 (51.3%) patients with hypertension, 107 (13.0%) with diabetes mellitus but not metabolic syndrome, 160 (19.4%) with metabolic syndrome but not diabetes mellitus, and 235 (28.5%) with both diabetes mellitus and metabolic syndrome. After 6 weeks of ezetimibe coadministration with statin therapy, mean E-RCAD was reduced by 4.1% from 15.6% to 11.5%, which is equivalent to a 25.3% risk reduction (p < 0.001). Of the 225 (27.3%) patients with high E-RCAD (≥20.1%) at baseline, 144 (64.0%) converted to a lower E-RCAD category (p < 0.001). Patients with both diabetes mellitus and metabolic syndrome experienced the highest mean percent reduction in E-RCAD of –29.4% (p < 0.001). Conclusions: For patients with above-target LDL-C levels while on statin monotherapy, coadministration of ezetimibe with the statin is effective in significantly reducing the E-RCAD.

Download Full-text